- 
                            From the CEOIn the past year, Analysis Group helped our clients in business and litigation matters in virtually every sector of the economy. Our clients consistently come to us for the range and depth of our expertise. In this issue, we highlight examples of our work both in and out of the courtroom. Statistical modeling was our assignment in the high-profile NFL “Deflategate” matter. The Greek sovereign debt crisis required analyzing effects on bond markets. Intellectual property work continued to expand, both in the context of the tools applied – such as the growing reliance on market research – and with respect to evaluating significant changes in the patent enforcement system. Our firm continues to grow, and we are committed to maintaining a distinctive, collaborative culture that allows us to draw on the best ideas to help our clients succeed. — Martha S. Samuelson, President and CEO 
- 
                            Statistics and Sports: “Deflategate”Statistical analysis of football pressure data contributes to a successful outcome for the NFLPA at U.S. District Court.   
- 
                            Forecasting Corporate Failure: A Look at Statistical and Theoretical ApproachesAndrew Wong and Konstantin Danilov assess the uses of major types of bankruptcy prediction models.   
- 
                            The Myth of Divided Antitrust EconomicsPierre Cremieux and Aaron Yeater reflect on the causes of discord and agreement among antitrust experts.   
- 
                            A Closer Look at the Use of Consumer Surveys in LitigationRebecca Kirk Fair and Laura O’Laughlin identify questions to consider when using surveys in litigation.   
- 
                            The Reality of US Pharmaceutical SpendingResearch by Paul Greenberg and Tamar Sisitsky explores perceived and actual US pharmaceutical spending.   
- 
                            Assessing the EPA’s Clean Power PlanRegional initiatives to regulate CO2 emissions may help US states meet new national standards.   
- 
                            Wolf Pack Activism: A Quick LookGaurav Jetley and Xinyu Ji consider activist hedge fund investors’ strategies.   
- 
                            Assessing Commercial Success at the US Patent Trial and Appeal BoardJohn Jarosz and Robert Vigil discuss the challenges patent owners face amid US patent enforcement changes.   
Case Outcomes
- 
                                    Recent LitigationIn 2015, Analysis Group worked with top law firms, Fortune 500 companies, global health care corporations, and government agencies in complex matters across industries. DISH Network Wins Multiple Victories in High-Profile Copyright Infringement MatterMorgan Stanley Cleared in Insider Trading DisputePartners HealthCare System’s Proposed Acquisition Settlement Rejected by Massachusetts Superior CourtJury Finds That Google Did Not Infringe Digital Rights Management PatentsInternational ExperienceAnalysis Group has worked on behalf of government and private organizations in diverse matters involving regulatory authorities, government agencies, and international arbitration entities on every continent. Investment Claims against Greek Government DismissedCanadian Telecom Regulator Mandates Wholesale Fibre Broadband Access
Also on analysisgroup.com
- 
                                    Fiduciary Monitoring Post-“Tibble”The 2015 Supreme Court decision in Tibble v. Edison International, which states that plan fiduciaries have a responsibility to monitor investments and remove imprudent ones, highlights the importance of appropriate plan fiduciary monitoring. In their article, “Expert Analysis: Using Simulation to Assist Courts in Assessing the Prudence of Retirement Plan Investment Decisions,” Managing Principal D. Lee Heavner and affiliate Susan Mangiero describe approaches that experts use to evaluate issues related to the procedural and substantive prudence of the selection of a retirement plan investment. Antitrust Experts File Amici Curiae BriefsIn the past year, groups of prominent economists have filed amici curiae briefs regarding the antitrust treatment of pharmaceutical patent infringement settlements, and a pharmaceutical manufacturer’s freedom to withdraw a branded product from the market prior to generic entry. 
 
        